Ilise Lombardo

Ilise Lombardo is the CEO of Noema Pharma, a Basel-based clinical-stage biotech advancing treatments for central nervous system disorders. A Yale-trained psychiatrist with a Cambridge M.Phil and a Brown degree, she spent two decades in clinical practice and academia before co-founding Arvelle Therapeutics, which sold to Angelini Pharma for roughly $1 billion in 2021. She now steers Noema's pipeline of Phase 2 programs targeting Tourette syndrome, trigeminal neuralgia, tuberous sclerosis seizures and menopause-related CNS symptoms.